Novartis Investigative Site

Summary

Novartis Investigative Site is a medical facility located in Richmond, Virginia. This center is recognized for care of I Am A Healthy Volunteer, Chronic Obstructive Pulmonary Disease, Atopic Dermatitis, Flu, Coronavirus and other specialties. Novartis Investigative Site is involved with conducting 145 clinical trials across 140 conditions. There are 6 research doctors associated with this hospital, such as Omer Khalid, Kara Foster-Weiss, Call, Robert, and Leroy Vaughan.

Top PIs

Clinical Trials running at Novartis Investigative Site

Celiac Disease

I Am A Healthy Volunteer

COVID-19

Obesity

Coronavirus Infection

Coronavirus

Lyme Disease

Type 2 Diabetes

Pulmonary Disease

Upper Respiratory Tract Infection

Amlitelimab

for Celiac Disease

This is a Phase 2a/b, randomized, double-blind, placebo-controlled, parallel-group, 6-arm study to evaluate the efficacy and safety of amlitelimab in adult participants with non-responsive celiac disease (NRCD) who are on a gluten free diet (GFD) with and without simulated inadvertent gluten exposure (SIGE). The primary purpose of this study is to demonstrate the efficacy of subcutaneous (SC) amlitelimab in male and female participants (aged 18 to 75 years, inclusive) with NRCD. The study will assess the effect of amlitelimab when compared to placebo on gluten induced changes in the intestinal mucosa as measured by the villous height to crypt depth (Vh:Cd) ratio. The effect of amlitelimab on participant-reported celiac signs and symptoms along with the safety, tolerability, and pharmacokinetics of amlitelimab will also be studied. Study details include: The study duration will be up to 48 weeks (including a 16-week safety follow-up period) with 10 visits for participants who opt not to enter the optional long-term extension. The study duration will be up to 172 weeks (including an 8-week safety follow-up period) with 22 visits for participants who enter the optional long-term extension. The double-blind placebo-controlled treatment duration will be up to 28 weeks.

Recruiting

0 awards

Phase 2

4 criteria

VTP-1000

for Celiac Disease

GLU001 is a first-in-human clinical trial to assess the safety and tolerability of VTP-1000 for adults with celiac disease. This trial will assess VTP-1000 at various dose levels compared to placebo in a single ascending dose (SAD) and multiple ascending dose (MAD) format. Participants will be followed for a short period of time to assess the impact of VTP-1000 on their immune system (Adverse events, reactions in the blood, and physical exam differences). Participants enrolled in the MAD portion of the trial will undergo a gluten challenge to assess the impact exposure to gluten has on participants after administration of VTP-1000.

Recruiting

0 awards

Phase < 1

3 criteria